Evidence map›Paper›PMID 34552594›Full record

ArticleFrontiers in immunology2021

IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies.

Katherine M Audsley, Teagan Wagner, Clara Ta, Hannah V Newnes, Anthony C Buzzai, Samantha A Barnes, Ben Wylie, Jesse Armitage, Tsuneyasu Kaisho, Anthony Bosco and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Interferon-Based Therapeutics in Cancer Therapy: Past, Present, and Future.International journal of molecular sciences · 2025
    Review
  3. Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Mesenchymal Stem Cells in Cancer Therapy.Advances in experimental medicine and biology · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. In Situ Vaccination with Mitochondria-Targeting Immunogenic Death Inducer Elicits CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Mesenchymal stem/stromal cells in cancer therapy.Journal of hematology & oncology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Katherine M AudsleyTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Teagan WagnerTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Clara TaTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Hannah V NewnesTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Anthony C BuzzaiTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Samantha A BarnesTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Ben WylieTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Jesse ArmitageTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Tsuneyasu KaishoDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Anthony BoscoTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Alison McDonnellTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Mark CruickshankSchool of Biomedical Sciences, The University of Western Australia, Nedlands, WA, Australia.
Vanessa S FearTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Bree FoleyTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
Jason WaithmanTelethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia.
University of Western Australia · AUThe Kids Research Institute Australia · AUWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here we systematically compared the capacity of distinct type I IFN subtypes to enhance T cell responses to a whole-cell vaccination strategy in a pre-clinical murine model. We show that vaccination in combination with IFNβ induces significantly greater expansion of tumor-specific CD8

Indexed as

Adjuvants, ImmunologicAnimalsB7-H1 AntigenCancer VaccinesCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationFemaleImmune Checkpoint InhibitorsInterferon-betaLymphocyte ActivationLymphocytes, Tumor-InfiltratingMelanoma, ExperimentalMiceMice, Inbred C57BLMice, TransgenicAdjuvants, ImmunologicB7-H1 AntigenCancer VaccinesCd274 protein, mouseImmune Checkpoint InhibitorsInterferon-betaadjuvantcancer vaccinationCD8+ T cellscheckpoint blockadecross-primingIFNβimmunotherapytype I interferon

Identifiers

PMID34552594
PMCPMC8450325
OpenAlexW3198321985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.